Gao Feng, Zhao Yongcheng, Zhang Bin, Xiao Chunwei, Sun Zhanfa, Gao Yuan, Dou Xueyong
Department cardiovascular surgery, Xuzhou Cancer Hospital.
J Biomater Appl. 2022 Aug;37(2):303-314. doi: 10.1177/08853282221087102. Epub 2022 Apr 9.
Myocardial ischemia-reperfusion injury (MI/RI) refers to the clinical state of decreased coronary blood flow caused by various causes. The main pathogenesis of MI/RI is mitochondrial oxidative damage. In this study, we designed a novel mitochondrial targeted astaxanthin (AST) liposome, namely, STPP-AST-LIP, targeting mitochondria of H9c2 myocardial cells. STPP-AST-LIP not only reduced the production of mitochondrial reactive oxygen species (ROS), but also increased the survival rate of MI/RI H9c2 cells. In addition, rat experiments further confirmed that STPP-AST-LIP could improve myocardial cardiac function in MI/RI rats, significantly inhibited apoptosis of myocardial cells, and had a protective effect on the heart of rats after MI/RI.
心肌缺血再灌注损伤（MI/RI）是指由各种原因引起的冠状动脉血流减少的临床状态。MI/RI的主要发病机制是线粒体氧化损伤。在本研究中，我们设计了一种新型的线粒体靶向虾青素（AST）脂质体，即STPP-AST-LIP，靶向H9c2心肌细胞的线粒体。STPP-AST-LIP不仅减少了线粒体活性氧（ROS）的产生，还提高了MI/RI H9c2细胞的存活率。此外，大鼠实验进一步证实，STPP-AST-LIP可以改善MI/RI大鼠的心肌心功能，显著抑制心肌细胞凋亡，并对MI/RI后大鼠的心脏具有保护作用。
